Katsuki Arima Tiscoski
A5060197505- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Prostate Cancer Treatment and Research
- Economic and Financial Impacts of Cancer
- Monoclonal and Polyclonal Antibodies Research
- Bladder and Urothelial Cancer Treatments
- Inflammatory Biomarkers in Disease Prognosis
- Lung Cancer Treatments and Mutations
- Biomarkers in Disease Mechanisms
- Cancer, Lipids, and Metabolism
- Global Cancer Incidence and Screening
- PARP inhibition in cancer therapy
- Peptidase Inhibition and Analysis
- Health Systems, Economic Evaluations, Quality of Life
- Cancer and Skin Lesions
- Cancer Treatment and Pharmacology
- Gastric Cancer Management and Outcomes
- Estrogen and related hormone effects
- Viral-associated cancers and disorders
- Ovarian cancer diagnosis and treatment
- Genetic factors in colorectal cancer
- Chemotherapy-induced cardiotoxicity and mitigation
- Renal cell carcinoma treatment
- Gastrointestinal Tumor Research and Treatment
- Hormonal and reproductive studies
Yonsei University
2024
Irmandade da Santa Casa de Misericórdia de São Paulo
2022-2023
The University of Texas MD Anderson Cancer Center
2023
AstraZeneca (Brazil)
2023
Santa Casa de Misericórdia de Marília
2022
Universidade Federal de Ciências da Saúde de Porto Alegre
2022
Santa Casa Hospital
2021
Immunotherapy and chemotherapy combinations have shown activity in endometrial cancer, with greater benefit mismatch repair (MMR)-deficient (dMMR) than MMR-proficient (pMMR) disease. Adding a poly(ADP-ribose) polymerase inhibitor may improve outcomes, especially pMMR
PURPOSE For patients with metastatic hormone-sensitive prostate cancer (mHSPC), delaying progression to castration-resistant disease is important not only for overall survival (OS) but also patients' quality of life. Darolutamide plus androgen-deprivation therapy (ADT) docetaxel improved OS versus ADT and in mHSPC. The ARANOTE trial evaluated darolutamide without chemotherapy METHODS In this global phase III trial, were randomly assigned 2:1 receive 600 mg twice daily or placebo, concomitant...
PURPOSE To compare giredestrant and physician's choice of endocrine monotherapy (PCET) for estrogen receptor–positive, HER2-negative, advanced breast cancer (BC) in the phase II acelERA BC study (ClinicalTrials.gov identifier: NCT04576455 ). METHODS Post-/pre-/perimenopausal women, or men, age 18 years older with measurable disease/evaluable bone lesions, whose disease progressed after 1-2 lines systemic therapy (≤1 targeted, ≤1 chemotherapy regimen, prior fulvestrant allowed) were randomly...
Introduction: The heterogeneous nature and intrinsically aggressive tumor pathology of the triple negative breast cancer subtype results in an unfavorable prognosis limited clinical success. use hematological components systemic inflammatory response for patients with triple-negative can add important prognostic information to criteria traditionally used patients, since inflammation promote progression support by affecting stages tumorigenesis. Objectives: aim this study was evaluate...
To estimate the cost of metastatic prostate cancer (mPC) treatment using time-driven activity-based costing (TDABC) method from perspective a philanthropic hospital in Brazilian public health system (PHS) and to identify determinants costs.We used data patients who received docetaxel chemotherapy PHS September 2012 May 2017. Direct medical costs were estimated with TDABC microcosting method, taking into account multiple departments services interacted during their oncological treatment.The...
The aim of this study was to evaluate the effectiveness in a real-world adjuvant trastuzumab women with HER-2+ initial breast cancer overall survival and recurrence-free survival. A retrospective cohort conducted who had treated from July 2012 May 2017 followed up until 2021. death rate 2.62 per 100 persons/year, incidence recurrence 7.52 persons/year. probability at 8.7 years 85.9%, while same period 62.8%. use proved be effective treatment public health service southern Brazil. Prognostic...
Breast cancer (BC) is the most prevalent in women Latin America and Caribbean.We compiled real-world data (RWD) on epidemiology, diagnosis, treatment, patient outcomes of triple-negative breast (TNBC), addressing main barriers to optimal care America.The prevalence TNBC varies between 11% 38.5% all BC cases diagnosed region, primarily affects young patients.Delays with consequent advanced disease stages access efficient therapies, particularly due high costs, negatively impact...
Abstract The aim of this study was to evaluate the effectiveness in a real-world adjuvant trastuzumab women with HER-2+ initial breast cancer overall survival and recurrence-free survival. A retrospective cohort conducted who had treated from July 2012 May 2017 followed up until 2021. death rate 2.62 per 100 persons/year, incidence recurrence 7.52 persons/year. probability at 8.7 years 85.9%, while same period 62.8%. use proved be effective treatment public health service southern Brazil....
Introduction: Plasmoblastic lymphoma (PBL) is a rare entity of non-Hodking that usually occurs in the oral cavity immunosuppressed patients. The involvement other organs has rarely been reported. breast can be site initial manifestation many diseases and cases like this report, lymphomas should considered as differential diagnoses. Case report: D.S., female, 28 years old, quality reviewer, married, two children. Carrier human immunodeficiency virus (HIV) with recent treatment. Intern for...